Vertex Pharmaceuticals Inc.’s (VRTX - Free Report) first-quarter 2014 loss came in at 85 cents per share (including stock-based compensation expense), much wider than the loss of 12 cents reported in the year-ago quarter. First quarter 2014 loss was also wider than the Zacks Consensus Estimate of a loss of 70 cents. Investors reacted negatively to the news with the stock falling 3.74%.
Excluding the impact of stock-based compensation expense, first quarter 2014 loss was 65 cents per share as against the year-ago earnings of 3 cents per share.
Vertex Pharma reported revenues of $108.2 million for the first quarter of 2014 (excluding hepatitis C virus/HCV revenues and royalties). Revenues were below the Zacks Consensus Estimate of $135 million.
We remind investors that in Nov 2013, Vertex Pharma sold its product royalty rights to its HCV treatment, Incivo (U.S. trade name: Incivek), to Janssen Pharmaceutica N.V., a Johnson & Johnson (JNJ - Free Report) company. Meanwhile, the company also announced that it has amended the terms of its agreement with Alios BioPharma regarding the development and commercialization of VX-135 for HCV. As per the amended agreement, Vertex plans to out-license VX-135 and cease further investment in its HCV pipeline.
The Quarter in Detail
Vertex Pharma’s first quarter revenues consisted of sales from Kalydeco ($99.5 million) and collaborative revenues ($8.7 million).
Vertex Pharma reported an increase of 61% in Kalydeco (cystic fibrosis) sales in the first quarter 2014 from the year-ago period. Rapid uptake among eligible patients in Europe and continued growth in the U.S. drove Kalydeco sales in the reported quarter. Additional growth should materialize with the conclusion of reimbursement discussions in Australia and Canada for eligible patients with the G551D mutation. Kalydeco revenues should also benefit from Vertex Pharma’s label expansion efforts.
In Feb 2014, Kalydeco was approved for treating patients suffering from cystic fibrosis who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
However, we note that Kalydeco revenues declined 8.7% sequentially as the fourth quarter of 2013 benefited from the favorable impact of stocking and other nonrecurring business adjustments.
Adjusted (including stock-based compensation expense) research and development (R&D) expenses for the quarter increased 0.2% to $214.4 million. First quarter 2014 adjusted (including stock-based compensation expense) selling, general and administrative (SG&A) expenses declined 27.9% to $66.1 million.
Apart from the first quarter 2014 results, Vertex Pharma provided an update on its pipeline. The company announced data from a 28-day phase II study evaluating VX-661 in combination with Kalydeco for the treatment of patients suffering from cystic fibrosis, who have both the F508del mutation and G551D mutation. The data revealed that the addition of VX-661 to Kalydeco resulted in statistically significant improvements in lung function in patients with both the F508del mutation and G551D mutation and who were already on Kalydeco.
A 12-week study of VX-661 plus Kalydeco is ongoing in patients with two copies of the F508del mutation.
Meanwhile, the company is also working on expanding Kalydeco’s label. The company plans to get Kalydeco approved for cystic fibrosis patients with at least one copy of the R117H mutation. Data from two phase III studies (TRAFFIC and TRANSPORT) evaluating Kalydeco plus VX-809 for cystic fibrosis patients with two copies of the F508del mutation, are expected in mid 2014. The company also plans to submit regulatory applications in the U.S. and EU later in 2014, subject to favorable data.
Vertex Pharma reduced its 2014 total revenue guidance. The company now expects revenues in the range of $520 million to $550 million (previous guidance: $570 million to $600 million). Pre-earnings, the Zacks Consensus Estimate for 2014 was $563 million, above the company’s guidance range.
Vertex Pharma continues to expect Kalydeco revenues in the range of $470 million to $500 million in 2014. The guidance assumes the conclusion of reimbursement discussions in Australia and Canada and potential label expansion of Kalydeco.
The company lowered its guidance for operating expenses (excluding stock-based compensation expense) to the range of $890 million to $930 million from the prior range of $900 million to $950 million. The anticipated decrease in operating expenses is primarily due to the termination of further investment in the HCV pipeline.
Vertex Pharma’s first quarter results were disappointing with the company posting a wider loss. Revenues were also impacted by the discontinuation of Incivo royalties.
We believe the termination of development activities related to the HCV pipeline is a strategic move by Vertex Pharma to cut its losses considering the fact that significant advancements have been made in HCV treatment with introduction of new oral treatments.
We note that HCV is a highly crowded market led by Gilead Sciences’ (GILD - Free Report) oral drug Sovaldi, which reported whopping revenues of approximately $2.3 billion in the first quarter of 2014. This is impressive considering that it was the first full quarter for Sovaldi, which was launched in Dec 2013. Moreover, Gilead is seeking approval for its once-daily fixed-dose HCV cocktail treatment, ledipasvir plus Sovaldi. Other companies such as Bristol-Myers Squibb Company (BMY - Free Report) are also looking to get their all-oral combinations approved.
For Vertex, Kalydeco revenues should keep growing with launches in Australia and Canada and expansion into additional patient populations. Vertex Pharma has a series of Kalydeco related events lined up in the coming quarters and we expect investor focus to remain on pipeline progress.
Vertex Pharma carries a Zacks Rank #3 (Hold). Gilead is a better-ranked stock with a Zacks Rank #1 (Strong Buy).